Home › Clinical Trials › Cancer Clinical Trial › Pancreas › A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Print
A A A

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Protocol Number: UCI-15-94

NCT Number: NCT02715804

Condition/Disease: Cancer - Pancreas

Principal Investigator: Jason Zell

Status: Open

Treatment: Treatment

Drugs: PEGPH20, Placebo

Phase: III

Age Group: Adult

Scope: Local

Learn More:
For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.